Related Experiment Videos
Is cyclophosphamide self-defeating as an antitumor agents?
Journal of Cancer Research and Clinical Oncology
|January 1, 1980
Summary
Intragastric tumor cell immunization can inhibit cyclophosphamide (CPA) antitumor effects in mice. This suggests tumor antigenicity may be crucial for successful CPA therapy, potentially by modulating tumor cell determinants.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Cyclophosphamide (CPA) is a common chemotherapeutic agent.
- Mammary carcinomas are a prevalent cancer type.
- Tumor-specific antigens play a role in immune response.
Purpose of the Study:
- To investigate the effect of prior intragastric tumor cell immunization on CPA's efficacy.
- To explore the role of tumor antigenicity in CPA therapy.
Main Methods:
- Mice with mammary carcinomas were immunized via intragastric inoculation of tumor cells.
- The antitumor effect of cyclophosphamide (CPA) was assessed in immunized and control mice.
Main Results:
- Intragastric immunization inhibited the antitumor effect of cyclophosphamide (CPA).
- Tumor cell immunization modulated antigenic determinants on tumor cells.
Conclusions:
- Tumor antigenicity is a critical factor influencing the success of cyclophosphamide (CPA) therapy.
- Modulation of tumor cell antigenicity can impair CPA's therapeutic efficacy.